Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
2.

Incidence of and risk factors for venous thrombosis in children with percutaneous non-tunnelled central venous catheters.

Östlund Å, Fläring U, Norberg Å, Dahlberg A, Berner J, Kaiser S, Vermin L, Svenningsson A, Frisk T, Larsson P, Andersson A.

Br J Anaesth. 2019 Jun 5. pii: S0007-0912(19)30342-3. doi: 10.1016/j.bja.2019.04.055. [Epub ahead of print]

PMID:
31176448
3.

Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.

Söderholm J, Yilmaz A, Svenningsson A, Büsch K, Wejstål R, Brolund A, Kövamees J, Sällberg M, Lagging M, Gisslén M.

J Neurol. 2019 May 31. doi: 10.1007/s00415-019-09397-8. [Epub ahead of print]

PMID:
31152298
4.

Population-based cohort study of the correlation between provision of care and the risk for complications after appendectomy in children.

Almström M, Svensson JF, Svenningsson A, Hagel E, Wester T.

J Pediatr Surg. 2019 Mar 28. pii: S0022-3468(19)30221-0. doi: 10.1016/j.jpedsurg.2019.03.013. [Epub ahead of print]

5.

Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease.

Feresiadou A, Nilsson K, Ingelsson M, Press R, Kmezic I, Nygren I, Svenningsson A, Niemelä V, Gordh T, Cunningham J, Kultima K, Larsson A, Burman J.

J Neuroimmunol. 2019 Jul 15;332:31-36. doi: 10.1016/j.jneuroim.2019.03.015. Epub 2019 Mar 25.

PMID:
30928869
6.

Inflammatory activity and vitamin D levels in an MS population treated with rituximab.

Linden J, Granåsen G, Salzer J, Svenningsson A, Sundström P.

Mult Scler J Exp Transl Clin. 2019 Feb 11;5(1):2055217319826598. doi: 10.1177/2055217319826598. eCollection 2019 Jan-Mar.

7.

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J.

Eur J Neurol. 2019 Aug;26(8):1060-1067. doi: 10.1111/ene.13936. Epub 2019 Mar 12.

PMID:
30762259
8.

Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.

de Flon P, Laurell K, Sundström P, Blennow K, Söderström L, Zetterberg H, Gunnarsson M, Svenningsson A.

Acta Neurol Scand. 2019 May;139(5):462-468. doi: 10.1111/ane.13078. Epub 2019 Mar 5.

PMID:
30740668
9.

Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.

Zetterberg H, Svenningsson A.

Neurology. 2019 Feb 12;92(7):313-314. doi: 10.1212/WNL.0000000000006906. Epub 2019 Jan 11. No abstract available.

PMID:
30635493
10.

Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.

Bergman J, Burman J, Gilthorpe JD, Zetterberg H, Jiltsova E, Bergenheim T, Svenningsson A.

Neurology. 2018 Nov 13;91(20):e1893-e1901. doi: 10.1212/WNL.0000000000006500. Epub 2018 Oct 10.

PMID:
30305449
11.

Population-based cohort study on the epidemiology of acute appendicitis in children in Sweden in 1987-2013.

Almström M, Svensson JF, Svenningsson A, Hagel E, Wester T.

BJS Open. 2018 Apr 19;2(3):142-150. doi: 10.1002/bjs5.52. eCollection 2018 Jun.

12.

Maternal risk factors and perinatal characteristics of anorectal malformations.

Svenningsson A, Gunnarsdottir A, Wester T.

J Pediatr Surg. 2018 Nov;53(11):2183-2188. doi: 10.1016/j.jpedsurg.2018.04.021. Epub 2018 Apr 17.

PMID:
29907315
13.

Early central line-associated blood stream infections in children with cancer pose a risk for premature catheter removal.

Moell J, Svenningsson A, Af Sandeberg M, Larsson M, Heyman M, Harila-Saari A, Nilsson A.

Acta Paediatr. 2019 Feb;108(2):361-366. doi: 10.1111/apa.14432. Epub 2018 Jun 27.

PMID:
29863780
14.

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.

de Flon P, Söderström L, Laurell K, Dring A, Sundström P, Gunnarsson M, Svenningsson A.

PLoS One. 2018 Feb 8;13(2):e0192516. doi: 10.1371/journal.pone.0192516. eCollection 2018.

15.

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F.

JAMA Neurol. 2018 Mar 1;75(3):320-327. doi: 10.1001/jamaneurol.2017.4011.

16.

Cortico-juxtacortical and periventricular lesions and MS diagnostic criteria.

Svenningsson A, Ciccarelli O.

Neurology. 2017 Dec 5;89(23):2308-2309. doi: 10.1212/WNL.0000000000004725. Epub 2017 Nov 3. No abstract available.

PMID:
29101273
17.

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, Malmeström C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J.

Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.

18.

In-hospital Surgical Delay Does Not Increase the Risk for Perforated Appendicitis in Children: A Single-center Retrospective Cohort Study.

Almström M, Svensson JF, Patkova B, Svenningsson A, Wester T.

Ann Surg. 2017 Mar;265(3):616-621. doi: 10.1097/SLA.0000000000001694.

PMID:
28169930
19.

Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature.

Vågberg M, Granåsen G, Svenningsson A.

PLoS One. 2017 Jan 17;12(1):e0170018. doi: 10.1371/journal.pone.0170018. eCollection 2017. Review.

20.

How to minimize the risk for headache? A lumbar puncture practice questionnaire study.

Salzer J, Rajda C, Sundström P, Vågberg M, Vécsei L, Svenningsson A.

Ideggyogy Sz. 2016 Nov 30;69(11-12):397-402. doi: 10.18071/isz.69.0397.

PMID:
29733557
21.

Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.

de Flon P, Laurell K, Söderström L, Gunnarsson M, Svenningsson A.

Mult Scler. 2017 Aug;23(9):1249-1257. doi: 10.1177/1352458516676643. Epub 2016 Oct 25.

PMID:
27780912
22.

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A.

Neurology. 2016 Nov 15;87(20):2074-2081. Epub 2016 Oct 19.

23.

Brain parenchymal fraction in an age-stratified healthy population - determined by MRI using manual segmentation and three automated segmentation methods.

Vågberg M, Ambarki K, Lindqvist T, Birgander R, Svenningsson A.

J Neuroradiol. 2016 Dec;43(6):384-391. doi: 10.1016/j.neurad.2016.08.002. Epub 2016 Oct 5.

PMID:
27720265
24.

Population-based study shows that Hirschsprung disease does not have a negative impact on education and income.

Granström AL, Svenningsson A, Nordenskjöld A, Wester T.

Acta Paediatr. 2016 Dec;105(12):1508-1512. doi: 10.1111/apa.13594. Epub 2016 Oct 9.

PMID:
27639057
25.

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.

Vågberg M, Axelsson M, Birgander R, Burman J, Cananau C, Forslin Y, Granberg T, Gunnarsson M, von Heijne A, Jönsson L, Karrenbauer VD, Larsson EM, Lindqvist T, Lycke J, Lönn L, Mentesidou E, Müller S, Nilsson P, Piehl F, Svenningsson A, Vrethem M, Wikström J.

Acta Neurol Scand. 2017 Jan;135(1):17-24. doi: 10.1111/ane.12667. Epub 2016 Aug 24. Review.

26.

Reply.

Alping P, Frisell T, Svenningsson A, Piehl F.

Ann Neurol. 2016 Nov;80(5):791-792. doi: 10.1002/ana.24767. Epub 2016 Sep 27. No abstract available.

PMID:
27553863
27.

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS.

Bergman J, Dring A, Zetterberg H, Blennow K, Norgren N, Gilthorpe J, Bergenheim T, Svenningsson A.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 2;3(5):e271. doi: 10.1212/NXI.0000000000000271. eCollection 2016 Oct.

28.

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.

de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundström P, Svenningsson A.

Neurology. 2016 Jul 12;87(2):141-7. doi: 10.1212/WNL.0000000000002832. Epub 2016 Jun 17.

PMID:
27316241
29.

Maternal Risk Factors and Perinatal Characteristics for Hirschsprung Disease.

Löf Granström A, Svenningsson A, Hagel E, Oddsberg J, Nordenskjöld A, Wester T.

Pediatrics. 2016 Jul;138(1). pii: e20154608. doi: 10.1542/peds.2015-4608. Epub 2016 Jun 15.

30.

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, Svenningsson A, Piehl F.

Ann Neurol. 2016 Jun;79(6):950-8. doi: 10.1002/ana.24651. Epub 2016 Apr 20.

PMID:
27038238
31.

Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.

Burman J, Svenningsson A.

J Neuroimmunol. 2016 Mar 15;292:40-4. doi: 10.1016/j.jneuroim.2016.01.008. Epub 2016 Jan 16.

PMID:
26943957
32.

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.

Al Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim T, Romme Christensen J, Sellebjerg F, Svenningsson A, Linington C, Olsson T, Piehl F.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e191. doi: 10.1212/NXI.0000000000000191. eCollection 2016 Feb.

33.

Rituximab in paediatric onset multiple sclerosis: a case series.

Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A.

J Neurol. 2016 Feb;263(2):322-326. doi: 10.1007/s00415-015-7979-x. Epub 2015 Nov 24.

PMID:
26603152
34.

Vitamin D and axonal injury in multiple sclerosis.

Sandberg L, Biström M, Salzer J, Vågberg M, Svenningsson A, Sundström P.

Mult Scler. 2016 Jul;22(8):1027-31. doi: 10.1177/1352458515606986. Epub 2015 Oct 13.

PMID:
26462862
35.

Outcomes in infants with prenatally diagnosed gastroschisis and planned preterm delivery.

Mesas Burgos C, Svenningsson A, Vejde JH, Granholm T, Conner P.

Pediatr Surg Int. 2015 Nov;31(11):1047-53. doi: 10.1007/s00383-015-3795-8. Epub 2015 Sep 23.

PMID:
26399421
36.

Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden.

Wickström A, Sundström P, Wickström L, Dahle C, Vrethem M, Svenningsson A.

Mult Scler J Exp Transl Clin. 2015 Sep 22;1:2055217315608203. doi: 10.1177/2055217315608203. eCollection 2015 Jan-Dec.

37.

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction.

Vågberg M, Norgren N, Dring A, Lindqvist T, Birgander R, Zetterberg H, Svenningsson A.

PLoS One. 2015 Aug 28;10(8):e0135886. doi: 10.1371/journal.pone.0135886. eCollection 2015.

38.

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light.

Al Nimer F, Thelin E, Nyström H, Dring AM, Svenningsson A, Piehl F, Nelson DW, Bellander BM.

PLoS One. 2015 Jul 2;10(7):e0132177. doi: 10.1371/journal.pone.0132177. eCollection 2015.

39.

Increasing prevalence of multiple sclerosis in Västerbotten County of Sweden.

Svenningsson A, Salzer J, Vågberg M, Sundström P, Svenningsson A.

Acta Neurol Scand. 2015 Dec;132(6):389-94. doi: 10.1111/ane.12408. Epub 2015 Apr 10.

PMID:
25857351
40.

[Swedish neurologists--unusually disobedient when it comes to lumbar punctures].

Salzer J, Vågber M, Svenningsson A, Sunddström P.

Lakartidningen. 2014 Oct 1-7;111(40):1725. Swedish. No abstract available.

41.

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.

Penner IK, Sivertsdotter EC, Celius EG, Fuchs S, Schreiber K, Berkö S, Svenningsson A; TYNERGY trial investigators.

Front Neurol. 2015 Feb 23;6:18. doi: 10.3389/fneur.2015.00018. eCollection 2015.

42.

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.

Svenningsson A, Bergman J, Dring A, Vågberg M, Birgander R, Lindqvist T, Gilthorpe J, Bergenheim T.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e79. doi: 10.1212/NXI.0000000000000079. eCollection 2015 Apr.

43.

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Burman J, Svensson E, Fransson M, Loskog AS, Zetterberg H, Raininko R, Svenningsson A, Fagius J, Mangsbo SM.

J Neuroimmunol. 2014 Dec 15;277(1-2):153-9. doi: 10.1016/j.jneuroim.2014.10.005. Epub 2014 Oct 18.

PMID:
25457841
44.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Svenningsson A, Sundstrom P, Salzer J, Vagberg M.

Neurology. 2014 Nov 25;83(22):2099-100. doi: 10.1212/01.wnl.0000457455.74798.9a. No abstract available. Erratum in: Neurology. 2015 Feb 24;84(8):862.

PMID:
25422402
45.

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC.

Mult Scler. 2015 Jul;21(8):1036-44. doi: 10.1177/1352458514556296. Epub 2014 Nov 12.

PMID:
25392339
46.

Lumbar puncture preferences among Swedish neurologists.

Salzer J, Sundström P, Vågberg M, Svenningsson A.

Neurol Res. 2015 Jan;37(1):92-4. doi: 10.1179/1743132814Y.0000000442. Epub 2014 Sep 12.

PMID:
25213597
47.

Maternal and pregnancy characteristics and risk of infantile hypertrophic pyloric stenosis.

Svenningsson A, Svensson T, Akre O, Nordenskjöld A.

J Pediatr Surg. 2014 Aug;49(8):1226-31. doi: 10.1016/j.jpedsurg.2014.01.053. Epub 2014 Feb 10.

PMID:
25092081
48.

Age-dependent effects on the treatment response of natalizumab in MS patients.

Matell H, Lycke J, Svenningsson A, Holmén C, Khademi M, Hillert J, Olsson T, Piehl F.

Mult Scler. 2015 Jan;21(1):48-56. doi: 10.1177/1352458514536085. Epub 2014 May 27.

PMID:
24866201
49.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21. doi: 10.1136/jnnp-2013-307207. Epub 2014 Feb 19.

PMID:
24554104
50.

Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.

Wickström A, Dahle C, Vrethem M, Svenningsson A.

Mult Scler. 2014 Jul;20(8):1095-101. doi: 10.1177/1352458513517590. Epub 2013 Dec 30.

PMID:
24378984

Supplemental Content

Loading ...
Support Center